Selective serotonin reuptake inhibitors are still harmful and ineffective. Responses to the comments by Hieronymus et al

Acta Neuropsychiatr. 2019 Oct;31(5):276-284. doi: 10.1017/neu.2019.24.

Abstract

In this response, we address point by point the additional issues raised by Hieronymus et al. in their second round of critique of our systematic review on selective serotonin reuptake inhibitors for major depression. We repulse that we are biased or mistaken in any major ways. We acknowledge that we missed a few small, mostly unpublished trials, and we made a few minor errors in our systematic review. However, these omissions and errors neither have any impact on our overall results nor on our conclusions. The critique by Hieronymus et al. seems to raise questions about their understanding of the systematic review process, and, on several occasions, they wrongly claimed that we made errors. Our analyses should be impartial and free from any biases or prejudices as we do not have any obligation to support the interests of sponsors or other groups.

Keywords: SSRI; antidepressants; clinical trials; depression; serotonin.

Publication types

  • Comment

MeSH terms

  • Depressive Disorder, Major*
  • Humans
  • Selective Serotonin Reuptake Inhibitors*

Substances

  • Serotonin Uptake Inhibitors